Dr. Farhan S. Imran, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 124
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 274201
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Rochester General Hospital Rochester, NY
- Unity Hospital Rochester, NY
Medical groups
- Rochester General Hospital (1,182 clinicians)
- The Unity Hospital of Rochester (736 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 124
- Services billed
- 367
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 108 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 52 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 18 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Rochester, NY | 117 |
| Prednisone Other prescribers in Rochester, NY | 61 |
| Abiraterone Acetate | 59 |
| Prochlorperazine Maleate Other prescribers in Rochester, NY | 48 |
| Dexamethasone Other prescribers in Rochester, NY | 31 |
| Eliquis (apixaban) Other prescribers in Rochester, NY | 23 |
| Kisqali (ribociclib succinate) | 21 |
| Tamoxifen Citrate Other prescribers in Rochester, NY | 20 |
| Letrozole Other prescribers in Rochester, NY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $173 in total to this clinician.
| Celgene Corporation | $68.23 |
|---|---|
| Pfizer Inc. | $61.30 |
| Merck Sharp & Dohme LLC | $24.25 |
| AstraZeneca Pharmaceuticals LP | $19.50 |
| Food and Beverage | $112 |
|---|---|
| Education | $61.30 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Aug 12, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
| Pfizer Inc. Oct 21, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $13,026 in research payments for these studies, mostly to the institutions running them.
- A phase iii multicenter randomized open label study comparing atezolizumab anti pd L1 antibody
Hoffmann-la Roche Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.